{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:04:18Z","timestamp":1761764658879,"version":"build-2065373602"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T00:00:00Z","timestamp":1144281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess the effects of two doses of botulinum toxin A (Dysport\u00ae, Ipsen\u2010Biotech, France; 500 and 1000 Speywood units, SU) injected into the bladder for treating incontinence due to a neurogenic overactive bladder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>In an open\u2010label, prospective study between October 2002 and May 2004, in two centres, we analysed the effects of successive doses of 500 and 1000 SU of Dysport, endoscopically injected into the detrusor muscle. At each step, patients (26 women and 19 men) were re\u2010evaluated at 1\u2003month (clinical evaluation and pressure\u2010flow study). If there was a \u2018good\u2019 clinical response (complete absence of urinary leakage) the patient was observed until incontinence recurred; otherwise a further injection was administered at a higher dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The mean (\n                      <jats:sc>sd<\/jats:sc>\n                      , range) follow\u2010up was 22\u2003(0.75, 5\u201331)\u2003months; 11 of the 45 patients (24%) did not respond primarily at 1\u2003month for both doses. The analysis of the two curves of survival with no re\u2010injection of Dysport showed a statistically longer action at 1000\u2003SU (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.016). However, in this group there was one patient with general muscle weakness and asthenia, which could have been related to the injection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The optimum dose of Dysport for incontinence secondary to a neurogenic overactive bladder is not yet defined; 1000\u2003SU probably has a more prolonged effect than 500\u2003SU but exposes the patient to major complications. Further studies evaluating the clinical effect of 750\u2003SU of Dysport are necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06091.x","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T12:25:13Z","timestamp":1144326313000},"page":"1030-1034","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?"],"prefix":"10.1111","volume":"97","author":[{"given":"ALAIN","family":"RUFFION","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"OLIVIER","family":"CAPELLE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PHILIPPE","family":"PAPAREL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BEATRICE","family":"LERICHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ALBERT","family":"LERICHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PHILIPPE","family":"GRISE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,6]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"401","article-title":"Botulinum toxin A in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedure?","volume":"18","author":"Stohrer M","year":"1999","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.1.6"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10066"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1542\/peds.68.1.50","article-title":"Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations","volume":"68","author":"Santos JI","year":"1981","journal-title":"Pediatrics"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.26.040186.002235"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-002-0081-9"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10274"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00382-6"},{"key":"e_1_2_7_10_2","first-page":"964","article-title":"Motor nerve sprouting in human orbicularis muscle after botulinum A injection","volume":"31","author":"Holds JB","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.37.5.711"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1978.tb08654.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.07.011"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)62540-6"},{"key":"e_1_2_7_15_2","unstructured":"GiannantoniA NardicciV MaccioniLet al.Nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity before and after botulinum A toxin injections into the detrusor muscle.ICS and IUGA Congress.Paris 2004"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.12.004"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(05)80413-0"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.11.009"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67283-7"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00136-2"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000108892.35041.2d"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67013-9"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.834"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870030409"},{"key":"e_1_2_7_26_2","first-page":"444","article-title":"[Iatrogenic botulism. A complication to be taken into account in the treatment of child spasticity]","volume":"37","author":"Beseler\u2010Soto B","year":"2003","journal-title":"Rev Neurol"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101318"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06091.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06091.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:59:18Z","timestamp":1761739158000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06091.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,6]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06091.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06091.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2006,4,6]]},"assertion":[{"value":"2006-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}